


产品名称: BLU-554
产品别名: Fisogatinib

生物活性:																											
Description	Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC ₅₀ of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling[1][2].																										
IC₅₀ & Target	FGFR4 5 nM (IC ₅₀)																										
In Vivo	Tissue distribution of Fisogatinib (10 mg/kg; oral gavage; for 4 hours; FVB/NRj mice) in wild-type mice is as follows; tissue concentrations decreases in the order liver > kidney > small intestine > spleen > brain. The high Fisogatinib liver-to-plasma ratio suggests there is a relatively high amount of the drug being transported into the liver[1].																										
	Animal Model:	Wild type male mice(FVB/NRj, 11-14 weeks of age)[1]																									
	Dosage:	10 mg/kg																									
	Administration:	Oral gavage; for 4 hours (Pharmacokinetic study)																									
	Result:	Tissue concentrations decreased in the order liver > kidney > small intestine > spleen > brain.																									
	In Vitro: DMSO : ≥ 25 mg/mL (49.66 mM) * "≥" means soluble, but saturation unknown.																										
Solvent&Solubility	Preparing Stock Solutions <table border="1"> <thead> <tr> <th rowspan="2">Concentration</th> <th>Solvent</th> <th>Mass</th> <th rowspan="2">1 mg</th> <th rowspan="2">5 mg</th> <th rowspan="2">10 mg</th> </tr> <tr> <th></th> <th></th> </tr> </thead> <tbody> <tr> <td>1 mM</td> <td></td> <td>1.9866 mL</td> <td>9.9329 mL</td> <td>19.8657 mL</td> </tr> <tr> <td>5 mM</td> <td></td> <td>0.3973 mL</td> <td>1.9866 mL</td> <td>3.9731 mL</td> </tr> <tr> <td>10 mM</td> <td></td> <td>0.1987 mL</td> <td>0.9933 mL</td> <td>1.9866 mL</td> </tr> </tbody> </table>	Concentration	Solvent	Mass	1 mg	5 mg	10 mg			1 mM		1.9866 mL	9.9329 mL	19.8657 mL	5 mM		0.3973 mL	1.9866 mL	3.9731 mL	10 mM		0.1987 mL	0.9933 mL	1.9866 mL	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。		
Concentration	Solvent		Mass	1 mg				5 mg	10 mg																		
1 mM		1.9866 mL	9.9329 mL	19.8657 mL																							
5 mM		0.3973 mL	1.9866 mL	3.9731 mL																							
10 mM		0.1987 mL	0.9933 mL	1.9866 mL																							
In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液, 再依次添加助溶剂: ——为保证实验结果的可靠性, 澄清的储备液可以根据储存条件, 适当保存; 体内实验的工作液, 建议您现用现配, 当天使用; 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象, 可以通过加热和/或超声的方式助溶																											
1.请依序添加每种溶剂: 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: ≥ 2.5 mg/mL (4.97 mM); Clear solution 此方案可获得 ≥ 2.5 mg/mL (4.97 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例, 取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中, 混合均匀, 向上述体系中加入 50 μL Tween-80, 混合均匀; 然后继续加入 450 μL 生理盐水定容至 1 mL。																											
2.请依序添加每种溶剂: 10% DMSO→ 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.97 mM); Clear solution																											

	<p>此方案可获得 $\geq 2.5 \text{ mg/mL}$ (4.97 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水溶液中，混合均匀。</p> <p>3.请依序添加每种溶剂： 10% DMSO → 90% corn oil Solubility: $\geq 2.5 \text{ mg/mL}$ (4.97 mM); Clear solution</p> <p>此方案可获得 $\geq 2.5 \text{ mg/mL}$ (4.97 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p>
References	<p>[1]. Dogan-Topal B, et al. Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>J Chromatogr B Analyt Technol Biomed Life Sci.</i> 2019 Mar 15;1110-1111:116-123.</p> <p>[2]. Richard Kim, et al. First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation. <i>EJC.</i> December 2016, Volume 69, Supplement 1, Page S41.</p>



源叶生物